Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Expecting 20 to 30 pps in next 3-5 months
The PharmaCo folks will start accumulating in 2-3 months time
Republicans have chosen illicit Hempextracts over Cannabis
Overall, the party charter is against MJ
So voting D is the only way to get it passed
I like it getting consolidated and accumulated at these levels. The next 10x+ run will bring it between 20 to 30 based on these levels
All bets r off if GLP-1 results prove this delivery is better than NOVO or Elli Lilly
Expect anywhere from 40-75 at the minimum
Expecting $20-30 on +ve results and 40-75 on Bigpharma partnerships
Next 2-3 months are critical
Let's be realistic, it went to .65c and then to 6.85. , so this time avg being 2.50-3.00 as low, anywhere from 20-30 is the range it will surely go
If the news is tie up or partnership with some big pharma, I think 40-75 in 3 trading days, might even open @10+
This one is getting for 7-10x from these levels. Next stop $20-30.
And any big pharma partnership will take it to $40-75
60% haircut in a month from highs of $6
.85, not bad.
If it consolidated around 3, will go to 25 to 3 in the next major news
Still accept that last post provided it consolidates around 4 pps
But it seems someone is flooding mkt without shares or.shorts.have got it and just taking it back to where.it all started
Going back to 0.65
The next leg up will be 5-8 million daily volume and price, which is going 300-400%from these levels.
I am waiting on some big pharma or bug tobacco partnership that will take to 20 to 30x
That can happen anytime between now and year end
Warrants exercised have a holding period of 6 months
1.6 mil warrants have been exercised
Nothing goes straight up. It was profit taking on technicals.as.RSI was.oversold.
It will consolidate and move much higher , still expecting it to close 5-10% pull back today's close.
I think it will hit $20 in next 2 months and it's good it is going up slowly building new supports along the way
Easy $20-25 in 2 months
SKYE went from $2 to 18 on 24 mil OS in 4 days on phase 2 trial of cbd related glaucoma trial
Waiting for $20, it's true value just based on IP and product pipelines
I am.telling u , this one can go $20/- in one day,
KALA went from $3.50 to $56 in 3 days on IND approval
BTW I have a few lots at $36 and $26, along with a few hundred from 0.70 to 4.50
Comparing #KALA, and it's IND approval
2nd $78 is all.time high.so if the tech is good, then lending 10-20 mil for trials will be the simple bet that anybbig pharma can afford, and they don't have shell $1.8 bil like Novo Nordisk
This could be a breakout year and a multi bagger stock this year
I never thought bumka would be diluting shit out of existing shareholders, and nicotine.deal will provide for biotech r&d
Expecting $25-$30 on IND approval and settling at about $12-14 for long term for 2024. I won't be surprised if $78/- get's tested in 2024 on Pharma /Tobacco partnership news
KALA went 10x on IND approval, execting 6x to 10x.from these.levels
One.partner.announcement and.this will test all time.high $78
Well, LEXX is $78 to 1.50 , so I would say comparable. Expecting 6x to 10x. The main thing is partnering with someone for trials
Did KALA move 10x just on IND application
Also looking at the way TPST, ALT ,KALA etc have gone up by 20-30X on news and even retained more than half of their gains is what keeps me around. I think if this company surely does something +ve, this is will fly probably 30-40X of current PPS.
I don't have to , Bumka is very much following this board. As I said earlier, I want him to deliver results. So far "NOTHING" has been delivered.
The Poviva tea, Vegan/CBD bars , or Gummies or what no, nothing has worked. The only and final hope is Biotech arm or the Nicotine Arm that could act as Pivot.
Otherwise this company is going Bankrupt.
As someone had mentioned in the post earlier too, this is probably is his "Last Chance", the IND application and GLP-1 trials and if he sooner does not find partners willing to work with him, it is going to be very bad for existing shareholders.
It still baffles me that none of the Big Tobacco is working with Lexxy.
Why waste money in trials using offshore laboratories when they are not credited enough for Big Pharma/Big Tobacco to partner.
I am not going to Pump a stock just to get an exit or make some dough. I genuinely want Bumka to work his ASS OFF and full fill the promises or narratives that he has been showing folks. That guy is taking 300k salary and another 200k+ of free stock and options, the least I expect him is to deliver.
Its not funny, it is good to call it out, as I sure Bumka is going through these messages. So just addressing them in shareholder letter is not going to cut it out.
Ok if that was the case, u agree Bumka conned us into believing institutional investors have lined up. Folks r willing to partner etc.
So unless results are from.credited labs, it is also manipulated?
Hard to believe none from Big pharma or Big Tobacco jumping on it unless IND approval brings legitimacy to these trials
Doing trials offshore with a different set surely has its disadvantages.
Completely agree that Bumka is focusing on Biotech and not CPG's. But the thing is that CPG was a way to fund biotech's trails and not dilute the shit out of shareholders. I have been holding bag and clearly frustrated with Bumka and find it hard to trust his narratives.
For me as a layman if DHT which seems to be "The thing" and the best one as per results published so far, why are biotech's not investing at this low mcap. Its a chump change for Biotech or Tobacco companies to partner at this stage with Lexx instead of waiting out.
This shareholder letter is also visible to other's from Big Pharma / Big Tobacco, how come they are not jumping up and down on their seats looking al the human trials of Nicotine or GLP-1 or CBD or Antiviral or any of those. Cause I believe, we have increase the bioavailability in each of the cases and non of the results from any of the previously taken trials had anything to suggest anything negative abt it.
There are too many +ve streams , but none of them is materializing , so it is very frustrating. This stock should have been $30-40 and mcap of 300-400 mil when the revenue potential is in few billions at the least. Hard to explain the market or rather Market know's it that we long terms don't
Seems like Bunka is having time to go through board messages , can he then also address the failures. The whole Japan co deal worth 4.5 mil would have sponsored some of the R&D expense, but having little to no revenue even after all these years of proving how "DHT" is better than what they are using now does not add much to the confidence of existing shareholders.
Nicotine pouch / Tobacco industry is bigger than Diabetes/Hypertension combined, still with very positive results, not a single taker on anything to do with DHT.
How come Bumka is not able to explain these gaps that I can clearly see between vision and its execution in this shareholder letter.
The failures have not been explained to give enough confidence whether the newer initiatives will yield any +ve results.
There are small biotech's that have gone up 30x like TPST, KALA or ALT etc, especially knowing that DHT is better than the one Novo got for 1.8 bil, not sure why its competitors are not pursuing joint trails using DHT
With such low mcap, for companies that big and having to sponsor these planned trials is chump change of few mil 5-10mil and acquire 25-30% of Lexx biotech subsidiary. That's what is baffling ,why none of the big ones are approaching Bumka
Yes, I agree it is for future sales of 396k shares . Can u explain why is bumka.and others are willing to dump them if they r so confident about the prospects.of this company technology.
I think this S8 is one of not offering new securities, but rather selling by employees. They're dumping 396502 shares as reoffer, and giving themselves additional thru this S8
Can you explain the S-8 where insiders are dumping shares. I think Bumka now only owns 5% of shares and not 10%.
As I mentioned earlier, all the news is planned around dumping more shares in open market.
If the earlier test were not enough to get BigP interested in technology, why do you think this time things will be any different.
I agree Diabetes and HighBP is much bigger market, but still much less than Tobacco and it is hard to believe that after proving and publishing human trials and still none of Big Tobacco has not shown any interest, including the one who owns 12% (MO)
Surprising, just sometime back someone was saying bumka does not test whats trending, but it is clear he did test covid 19 antiviral , I think I saw more than 1 press release in past.
He did it for epidolex and also for anything that's out there by other pharma Co. But none of its competitors are going after lexx to bring competitive products through dehydratech
I just hope Bunka gets Big Pharma / Big Tobacco as interested in his vision and mission as he has got bunch of Long term share holders holding bags while he continues to profit from their HOPE
Bumka at his best, running con game with help of Ted and news wire, creating hope and anticipation of some big tobacco or big pharma will one day buy it out or seriously partner instead of TIEing their hands 😃
Looks like all the news are planned around shitty 10-Q
Ted has dropped another letter justifying why Altria has bought 12% of lexx nicotine and tied their hands , so that they can continue to use other product , but not the superior lexxy pouches .
It gets more interesting that now for next 6 months a new HOPE of GLP-1 study and data is created just like last year of hypertension ind application
Let's see if things will be done in 6 months or he will drag it to 1yr+ as he did for hypertension
I guess there is someone who is able to call out A spade a spade.
Can Bunka clear all the questions I have raised. If the test were carried out offshore to save $, why us there need to raise so much $.
Why can't Bumka focus on one thing and keeps on doing Animal studies for anything and everything.
He has proven his technique delivers better than GW pharma epidolex, but that didn't change the perception of big pharma
Similarly, for remesidivor or now glp-1
Or nicotine pouches
What is the catch or gap that we shareholders and warrant holders are not able to see and are constantly buying into narratives set by Ted and NewsWire
And are willingly holding bags for Home Run
Even if lexx follows TPST profile where it went up 30x on some approval or KALA 20x on IND approval, it is still going to be below $75 pps pre split high
If that was the case, how did the stock go all the way to 0.65 cents. Also why raise $ at 0.95 with a warrant too available at the same price.
Why reprice all the "Options" held by Bumka and his cronies, is he not confident of his "Dehyratech" technology.
If he has repriced his options, why not reprices the Warrants that were issued in 2021 at $6.75 that folks might have bought into believing his technology crap.
I think Bumka is setting the narrative through these NewsWire and Ted's quarterly letter to continue to fill his own coffers.
How do you know that he is not paying himself additional $$ as kickback for giving projects to offshore labs. How do you know that because he is using offshore university and labs for his "Animal" research, FDA is not going to entertain is IND application. Is that the reason why Big Pharma and Big Tobacco are scared to invest as the results could have been manipulated as they are not done from accredited vendor
Your answered it yourself, the results from those labs are not acceptable , as you mentioned , they Big Pharma /Tobacco are both doing their due diligence and signing contracts with other corporations but Lexxy. May be you might want to check why from Bumka who is not picking up phone except of Ted, who is a paid tout.
It does not change the fact that Bumka is taking y'all for ride. How come his Patented technology is not good enough to be considered investment worthy. I see that Altria invest $2 bil for nicotine pouches, Novo invested $1.8 bil as you mentioned for GLP-1, but no other competitor in Big Tobacco or Big Pharma is looking to check Dedhydra-tech.
Too bad, it seems Lexxy will jump on anything that's trending. Bumka just creates this HOPE with the animal study ,followed by small batch of human study to prove his point and get more folks like you to add more shares while he and his cronies sell shares and fill their coffers. I don't know how many more millions he will give to "Contract" work for R&D where he claims to have no control.
There is something missing in his narrative where the IND application data is not yet out which was suppose to come by Aug and it is delayed by 6 months.
So in those 6 months , the only thing trending was GLP-1 drugs, so lets start animal study.
https://ir.lexariabioscience.com/news-events/press-releases/detail/132/lexarias-dehydratechtm-enabled-remdesivir-and-ebastine